Powl Brian T. - 21 Aug 2026 Form 4 Insider Report for Kura Oncology, Inc. (KURA)

Reporting relationship: Chief Commercial Officer
Issuer ticker: KURA
Reported as of: 21 Aug 2026
Net transaction value: -$51,663
SEC form: 4
Accepted by SEC: 24 Aug 2026, 17:30:03 UTC
Prior SEC filing: 22 May 2026
Source filing: View source filing
Reporting owner signature: Teresa Bair, Attorney-in-fact for Brian Powl

Key filing fact

Powl Brian T. filed Form 4 for Kura Oncology, Inc. (KURA) on 24 Aug 2026.

Key facts

This page summarizes Powl Brian T.'s Form 4 filing for Kura Oncology, Inc. (KURA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 24 Aug 2026, 17:30.

Change

Previous filing in this sequence was filed on 22 May 2026.
Current net transaction value: -$51,663.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001934232 Primary reporting owner

Powl Brian T.

Relationship: Chief Commercial Officer
Address: C/O KURA ONCOLOGY, INC., 4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO
Signature: Teresa Bair, Attorney-in-fact for Brian Powl
Signature date: 24 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KURA transaction

Common Stock

Sale

Transaction value: $51,663
Shares: -4,345
Change %: -2.5%
Price: $11.89
Shares after: 169,269
Date: 21 Aug 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2025.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $11.78 to $12.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.